porhon, it could well be as you say, but tell me how did you come to speculate that. My understanding of cytostorms is weak but I did find this article below telling that Mdivi-1 attenuates acute lung injury and calms down pro-inflammatory cytokines mitochondrial fission. As you may remember PBT434 is chemically very similar to Mdivi-1 ( both quinazolinones ) and in experiments, both of these are working in similar ways.
IMO it would be a good thing if Sinclair would be investigating if PBT434 could calm down the lung problem in the COVID-19 cases.
Here is this paperdoi: 10.1016/j.pupt.2020.101918. Online ahead of print.Mdivi-1 Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting MAPKs, Oxidative Stress and Apoptosis
Songyun Deng 1 , Lina Zhang 2 , Yunan Mo 3 , Yan Huang 4 , Wenchao Li 5 , Qianyi Peng 6 , Li Huang 7 , Yuhang Ai 8Affiliations
- PMID: 32251714
- DOI: 10.1016/j.pupt.2020.101918
Abstract
Sepsis is among the most devastating events in intensive care units. As a complication of sepsis, acute lung injury (ALI) is common and highly associated with poor outcome. The present study demonstrated that abnormal mitochondrial dynamics play a pivotal role in lipopolysaccharide (LPS)-induced ALI. Inhibiting the mitochondrial fission with the specific inhibitor-1 (Mdivi-1) ameliorated ALI as assessed by hematoxylin and eosin (H&E) staining and wet/dry ratio. Furthermore, Mdivi-1 reduced mitogen-activated protein kinases (MAPKs) activation, oxidative stress and apoptosis in the lungs. Plasma pro-inflammation cytokines were also reduced significantly in Mdivi-1-treated mice. In vitro study revealed that Mdivi-1 protected the macrophages from LPS-induced MAPKs activation, oxidative stress and cell apoptosis. Mdivi-1 also inhibited the release of pro-inflammatory cytokines. Morphological analysis showed that Mdivi-1 rescued the macrophages from LPS-induced mitochondrial fragmentation. Moreover, LPS treatment induced significant phosphorylation of Drp1 at Ser616, dephosphorylation at Ser637 and translocation of Drp1 from the cytoplasm to mitochondria, while Mdivi-1 inhibited those effects. Thus, modification of fission to rebuild mitochondrial homeostasis may offer an innovative opportunity for developing therapeutic strategies against ALI.
- Forums
- ASX - By Stock
- ATH
- New iron chelators enhancing NAD+ NADPH ratio
New iron chelators enhancing NAD+ NADPH ratio, page-4
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $3.631K | 1.210M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
60 | 81072032 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 2447647 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
60 | 81072032 | 0.002 |
23 | 125810099 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 2447647 | 3 |
0.004 | 138755246 | 32 |
0.005 | 21959256 | 23 |
0.006 | 22031950 | 18 |
0.007 | 50806651 | 22 |
Last trade - 15.59pm 18/09/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |